Aenova is the company formed by the merger of two separate investments made by Bridgepoint: Swiss Caps, Europe’s No 2 contract soft capsule manufacturer of vitamins, minerals, supplements and pharma products, and Dragenopharm, a German contract manufacturer for the generic prescription drugs market.
Formed in 2006, Aenova now has the largest contract tablet manufacturing capacity in Europe for perscription and OTC drugs and nutritional supplements and is a leading producer of generic drugs. Combining both businesses created the opportunity to improve manufacturing efficiency, and through sharing technological know-how and IP, accelerate both product development and expansion of its customer base.
Under Bridgepoint ownership the company became a key partner for many of Europe's leading pharmaceutical companies.
In August 2012 Aenova was acquired by BC Partners for an undisclosed sum.
To learn more about the company, visit www.aenova.de